Loading...
XNAS
VTRS
Market cap10bUSD
Jul 11, Last price  
9.12USD
1D
-1.41%
1Q
20.95%
Jan 2017
-76.09%
Name

Viatris Inc

Chart & Performance

D1W1MN
P/E
P/S
0.73
EPS
Div Yield, %
3.95%
Shrs. gr., 5y
18.23%
Rev. gr., 5y
5.09%
Revenues
14.74b
-4.46%
1,253,374,0001,257,164,0001,611,819,0005,137,585,0005,092,785,0005,450,522,0006,129,825,0006,796,110,0006,909,143,0007,719,600,0009,429,300,00011,076,900,00011,907,700,00011,433,900,00011,500,500,00011,946,000,00017,886,300,00016,262,700,00015,426,900,00014,739,300,000
Net income
-634m
L
203,592,000184,542,000217,284,000-181,215,000232,571,000345,115,000536,810,000640,850,000623,711,000929,400,000847,600,000480,000,000696,000,000352,500,00016,800,000-669,900,000-1,269,100,0002,078,600,00054,700,000-634,200,000
CFO
2.30b
-17.74%
203,711,000416,561,000390,192,000384,447,000605,075,000931,404,000720,424,000949,018,0001,106,563,0001,014,800,0002,008,500,0002,047,200,0002,064,800,0002,341,700,0001,803,700,0001,231,800,0003,016,900,0002,952,600,0002,799,600,0002,302,900,000
Dividend
Aug 23, 20240.12 USD/sh
Earnings
Aug 06, 2025

Profile

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
IPO date
Feb 01, 1973
Employees
38,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
14,739,300
-4.46%
15,426,900
-5.14%
16,262,700
-9.08%
Cost of revenue
9,924,400
9,899,000
10,427,900
Unusual Expense (Income)
NOPBT
4,814,900
5,527,900
5,834,800
NOPBT Margin
32.67%
35.83%
35.88%
Operating Taxes
11,000
148,200
734,600
Tax Rate
0.23%
2.68%
12.59%
NOPAT
4,803,900
5,379,700
5,100,200
Net income
(634,200)
-1,259.41%
54,700
-97.37%
2,078,600
-263.79%
Dividends
(574,800)
(575,600)
(581,600)
Dividend yield
3.87%
4.40%
4.29%
Proceeds from repurchase of equity
(247,500)
(246,900)
(14,000)
BB yield
1.67%
1.89%
0.10%
Debt
Debt current
87,700
2,017,700
1,259,100
Long-term debt
16,244,500
16,601,900
18,277,200
Deferred revenue
2,432,000
Other long-term liabilities
1,351,500
(675,500)
Net debt
14,247,600
16,293,200
17,185,000
Cash flow
Cash from operating activities
2,302,900
2,799,600
2,952,600
CAPEX
(326,000)
(377,000)
(443,000)
Cash from investing activities
1,800,700
(764,100)
1,520,500
Cash from financing activities
(4,330,400)
(2,301,900)
(3,877,900)
FCF
8,114,900
3,057,600
3,832,500
Balance
Cash
734,800
1,184,400
1,259,900
Long term investments
1,349,800
1,142,000
1,091,400
Excess cash
1,347,635
1,555,055
1,538,165
Stockholders' equity
722,500
1,904,500
2,426,500
Invested Capital
33,978,800
38,635,045
40,285,335
ROIC
13.23%
13.63%
12.13%
ROCE
13.45%
13.18%
13.18%
EV
Common stock shares outstanding
1,193,300
1,206,900
1,217,400
Price
12.45
14.96%
10.83
-2.70%
11.13
-17.74%
Market cap
14,856,585
13.66%
13,070,727
-3.53%
13,549,662
-17.15%
EV
29,104,185
29,363,927
30,734,662
EBITDA
7,708,100
8,268,400
8,862,400
EV/EBITDA
3.78
3.55
3.47
Interest
550,000
573,100
592,400
Interest/NOPBT
11.42%
10.37%
10.15%